Initiated in 2010, Oncotarget began its origins as a traditional multidisciplinary journal with an inital focus on oncology.
There is one particular core value that separates Oncotarget stand out from most other journals: democratization.
Oncotarget has further demonstrated that it takes democratization core values seriously with the implementation of the Creative Commons Attribution 3.0 License.
This license openly allows fellow researchers to fully take the research studies from Oncotarget that have already been published with the added bonus of being able to share those published reports with other scientists in that field or in other fields that are of similiar or related interest.
One factor that is important to take into account is that Oncotarget focuses on more than just oncology primarily.
There are other topics of importance are of interest for Oncotarget such as gerotargeting, immunology, and other topics, as well.
Because of this open and free nature of how the research papers can be shared through the journal altogether, this allows for certain experiments to be finsihed more faster than it would if the published papers were more in a non-democratized manner.
The other side benefit is that this saves time.
This principle helps Oncotarget stay up-to-date with its offerings of published reports that it continues to update each and every day.
This is partly due to the democratization approach that Oncotarget is able to utilize which allows the expediency of the reports being shared among the open community. Follow Oncotarget journal on Twitter.
The success of Oncotarget has prompted us to launch sections beyond oncology – https://t.co/ccRO4O68Oj
— Oncotarget (@OncotargetJrnl) December 14, 2017
Going Forward with Oncotarget’s Media Objectives
Oncotarget continues to strive forward with its stated missions in regards to its media platform.
Previosuly, in 2017, Oncotarget had publicly stated that its goal was to transform its publication frequency from a mere weekly publication to a more twice-weekly media journal.
Needless to be said, the notable result would be the multidisciplinary journal has more entries in its journal. Of course, there is also another side-benefit to this as well.
Oncotarget’s readers would not have to be worried about hiatuses or gaps in the releases in the publication releases.
The next crowning accomplishment is that Oncotarget has created and premiered its own podcast.
The overall purpose of that podcast is to detail its findings in the published reports through the avenue of podcasting format.
Through the podcasting platform, people would be able to listen to latest developments through podcast.
These latest developments are available on the following podcasting platforms such as Stitcher, Soundcloud, Player.FM, and iTunes. Listen to Oncotarget podcast on Player.FM.
There are other achievements that Oncotarget has been responsible for, as well.
One rewarding accomplishment that Oncotarget researchers have been able to name proven new therapeutic strategies to treat thyroid cancer.
Oncotarget is still remaining indexed by most scientific databases such as Scopus, Embase, Biological Abstracts, and BIOSIS Previews.
Oncotarget’s rewarding accomplishments have been noticed.
Because of the free and open nature of the democratization concept that Oncotarget upholds, researchers are still able to move along with their experiments at a much more faster rate.
While holding onto the democratizing approach, Oncotarget is overly important with the accomplishments that they have been able to make.
Learn more: https://www.ncbi.nlm.nih.gov/pmc/journals/1558/